Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bone Disease
Skeletal imaging agent approved by FDA
April 6th, 2004
Draximage, Inc., the radiopharmaceutical subsidiary of Draxis Health, Inc., (DRAX) (DAX), has received approval from the U.S. Food and Drug Administration (FDA) to produce and market a new formulation of a diagnostic product for preparing a skeletal imaging agent that is used to demonstrate areas of altered osteogenesis or bone growth. This imaging agent is used, for example, in metastatic bone disease, Paget's disease, arthritic disease, and osteomyelitis. The newly formulated diagnostic product, called MDP-25, is a kit for the preparation of Technetium Tc 99m Medronate Injection (99m Tc-Methylene Diphosphonic Acid Kit). Each vial of MDP-25 contains...
Source: Cancer Weekly (2004-04-06)
|
